Key points
- The Advisory Committee on Immunization Practices (ACIP) develops recommendations on how to use vaccines to control disease in the United States.
- These recommendations become official CDC policy once adopted by CDC's Director.
- Learn about current and historical ACIP recommendations for Haemophilus influenzae Type b (Hib) vaccine.
Published in Morbidity and Mortality Weekly Report (MMWR)
The Advisory Committee on Immunization Practices (ACIP) provides advice and guidance to the Director of the CDC regarding use of vaccines and related agents for control of vaccine-preventable diseases in the civilian population of the United States. Recommendations made by the ACIP are reviewed by the CDC Director and, if adopted, are published as official CDC/HHS recommendations in the Morbidity and Mortality Weekly Report (MMWR).
CURRENT Hib Vaccine Recommendations
MMWR, September 12, 2024, Vol 73(36);799–802
Use of Haemophilus influenzae Type b–Containing Vaccines Among American Indian and Alaska Native Infants: Updated Recommendations of the Advisory Committee on Immunization Practices ― United States, 2024
Print version
MMWR, April 29, 2016, Vol 65(16);418–419
Food and Drug Administration Approval for Use of Hiberix as a 3-Dose Primary Haemophilus influenzae Type b (Hib) Vaccination Series
Print version
MMWR, February 28, 2014, Vol 63(RR-01);1-14
Prevention and Control of Haemophilus influenzae Type b Disease: Recommendations of the ACIP, 2014
Print version
- See also:
ARCHIVED Hib Immunization Publications
For your convenience, these archived publications can be used for historical and research purposes.
MMWR, September 18, 2009, Vol 58(36);1008-1009
Licensure of a Haemophilus influenzae Type b (Hib) Vaccine (Hiberix) and Updated Recommendations for Use of Hib Vaccine
Print version
MMWR, June 26, 2009, Vol 58(24);673-674
Updated Recommendations for Use of Haemophilus influenzae Type b (Hib) Vaccine: Reinstatement of the Booster Dose at Ages 12-15 Months
Print version
MMWR, December 21, 2007, Vol 56(50);1318-1320
Interim Recommendations for the Use of Haemophilus influenzae Type b (Hib) Conjugate Vaccines Related to the Recall of Certain Lots of Hib-Containing Vaccines (PedvaxHIB® and Comvax®)
Print version
MMWR, September 17, 1993, Vol 42(RR-13)
Recommendations for Use of Haemophilus b Conjugate Vaccines and a Combined Diphtheria, Tetanus, Pertussis, and Haemophilus b Vaccine
Print version
MMWR, January 11, 1991, Vol 40(RR01);1-7
Haemophilus b Conjugate Vaccines for Prevention of Haemophilus influenzae Type b Disease Among Infants and Children Two Months of Age and Older
(Print version not available)